|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
PT733103E
(pt)
|
1993-11-09 |
2004-07-30 |
Targeted Genetics Corp |
Criacao de elevados titulos de vectores de aav recombinantes
|
|
PT728214E
(pt)
|
1993-11-09 |
2004-11-30 |
Ohio Med College |
Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
|
|
US5658785A
(en)
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US5856152A
(en)
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
|
AU707866B2
(en)
|
1994-12-06 |
1999-07-22 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
|
FR2737730B1
(fr)
|
1995-08-10 |
1997-09-05 |
Pasteur Merieux Serums Vacc |
Procede de purification de virus par chromatographie
|
|
AU722196B2
(en)
|
1995-08-30 |
2000-07-27 |
Genzyme Corporation |
Chromatographic purification of adenovirus and AAV
|
|
EP1983057A3
(en)
|
1995-09-08 |
2009-01-07 |
Genzyme Corporation |
Improved AAV vectors for gene therapy
|
|
US5910434A
(en)
|
1995-12-15 |
1999-06-08 |
Systemix, Inc. |
Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
|
|
EP0932418B1
(en)
|
1996-09-06 |
2007-12-05 |
The Trustees Of The University Of Pennsylvania |
Method for recombinant adeno-associated virus-directed gene therapy
|
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
|
JP2001514845A
(ja)
|
1997-09-05 |
2001-09-18 |
ターゲティッド ジェネティクス コーポレイション |
組換えａａｖベクターの高力価ヘルパーなし調製物を生成するための方法
|
|
US6258595B1
(en)
|
1999-03-18 |
2001-07-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
|
CA2406743A1
(en)
|
2000-04-28 |
2001-11-08 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
|
|
AU2002248297A1
(en)
|
2001-01-05 |
2002-07-16 |
Children's Hospital, Inc. |
Aav2 vectors and methods
|
|
US20070225363A1
(en)
*
|
2003-11-21 |
2007-09-27 |
The University Of Newcastle Research Associates Ltd. |
Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis
|
|
WO2007056435A2
(en)
|
2005-11-08 |
2007-05-18 |
The General Hospital Corporation |
Dynamin mediated diseases and associated methods and products
|
|
US20080306007A1
(en)
*
|
2007-04-30 |
2008-12-11 |
Newcastle Innovation Limited |
Agents for prophylaxis or treatment of neurological related diseases and conditions
|
|
US20110081362A1
(en)
*
|
2008-01-31 |
2011-04-07 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer
|
|
US9434928B2
(en)
|
2011-11-23 |
2016-09-06 |
Nationwide Children's Hospital, Inc. |
Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
|
|
BR112018070249A2
(pt)
*
|
2016-04-02 |
2019-01-29 |
Research Institute At Nationwide Children's Hospital |
sistema promotor de u6 modificada para expressão específica de tecido
|
|
US10947540B2
(en)
|
2016-11-29 |
2021-03-16 |
Association Institut De Myologie |
Allele-specific silencing therapy for Dynamin 2-related diseases
|
|
EP3610016A1
(en)
|
2017-04-10 |
2020-02-19 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
|
WO2018200674A1
(en)
|
2017-04-26 |
2018-11-01 |
Mitobridge, Inc. |
Dynamin-1-like protein inhibitors
|
|
BR112020014425A2
(pt)
|
2018-01-15 |
2020-12-29 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão de dnm2
|